Novolog (Pharm-Up 1966) Statistics

Total Valuation

Novolog (Pharm-Up 1966) has a market cap or net worth of ILS 914.18 million. The enterprise value is 892.93 million.

Market Cap	914.18M
Enterprise Value	892.93M

Important Dates

The next estimated earnings date is Sunday, March 23, 2025.

Earnings Date	Mar 23, 2025
Ex-Dividend Date	Dec 2, 2024

Share Statistics

Novolog (Pharm-Up 1966) has 510.72 million shares outstanding. The number of shares has decreased by -0.33% in one year.

Current Share Class	n/a
Shares Outstanding	510.72M
Shares Change (YoY)	-0.33%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	8.61%
Owned by Institutions (%)	59.84%
Float	330.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.53
PB Ratio	2.42
P/TBV Ratio	13.89
P/FCF Ratio	20.74
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.74, with an EV/FCF ratio of 20.26.

EV / Earnings	-147.67
EV / Sales	0.52
EV / EBITDA	5.74
EV / EBIT	13.60
EV / FCF	20.26

Financial Position

The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.52.

Current Ratio	0.97
Quick Ratio	0.83
Debt / Equity	0.52
Debt / EBITDA	1.27
Debt / FCF	4.61
Interest Coverage	4.16

Financial Efficiency

Return on equity (ROE) is -1.00% and return on invested capital (ROIC) is 6.93%.

Return on Equity (ROE)	-1.00%
Return on Assets (ROA)	1.41%
Return on Capital (ROIC)	6.93%
Revenue Per Employee	1.81M
Profits Per Employee	-6,332
Employee Count	955
Asset Turnover	0.56
Inventory Turnover	5.54

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.93% in the last 52 weeks. The beta is 0.37, so Novolog (Pharm-Up 1966)'s price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+19.93%
50-Day Moving Average	164.12
200-Day Moving Average	153.90
Relative Strength Index (RSI)	66.95
Average Volume (20 Days)	214,268

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novolog (Pharm-Up 1966) had revenue of ILS 1.73 billion and -6.05 million in losses. Loss per share was -0.01.

Revenue	1.73B
Gross Profit	179.34M
Operating Income	69.49M
Pretax Income	9.87M
Net Income	-6.05M
EBITDA	136.29M
EBIT	69.49M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 239.95 million in cash and 203.34 million in debt, giving a net cash position of 36.61 million or 0.07 per share.

Cash & Cash Equivalents	239.95M
Total Debt	203.34M
Net Cash	36.61M
Net Cash Per Share	0.07
Equity (Book Value)	393.14M
Book Value Per Share	0.74
Working Capital	-89.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 103.77 million and capital expenditures -59.70 million, giving a free cash flow of 44.07 million.

Operating Cash Flow	103.77M
Capital Expenditures	-59.70M
Free Cash Flow	44.07M
FCF Per Share	0.09

Full Cash Flow Statement

Margins

Gross margin is 10.38%, with operating and profit margins of 4.02% and -0.35%.

Gross Margin	10.38%
Operating Margin	4.02%
Pretax Margin	0.57%
Profit Margin	-0.35%
EBITDA Margin	7.89%
EBIT Margin	4.02%
FCF Margin	2.55%

Dividends & Yields

This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 2.19%.

Dividend Per Share	0.04
Dividend Yield	2.19%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.33%
Shareholder Yield	2.52%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novolog (Pharm-Up 1966) has an Altman Z-Score of 0.77. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.77
Piotroski F-Score	n/a